Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The funding will support DPUK's work in bridging the gaps between discoveries in the lab, trials and new treatments for dementia.

A public-private partnership, DPUK brings together expertise from universities, charities, pharmaceutical and technology companies to enable crucial breakthroughs in dementia research, quickening the translation of these discoveries into viable patient treatments. 

Based at the University of Oxford, DPUK has key parts of its work centred at the University of Cambridge and Population Data Science at Swansea University as well as elsewhere in the UK.

DPUK’s Data Portal, which is hosted at Swansea University, is a world-leading Trusted Research Environment (TRE) available to researchers globally to access data to find new ways of detecting, treating and preventing dementia. It currently has more than 60 datasets and the analysis environment to work on the records on over 3.5 million people.

ADDI is a not-for-profit organisation committed to accelerating advances in Alzheimer’s disease and related dementias by supporting greater access to data and the tools required to analyse it. It offers researchers around the world access, at no cost, to resources such as the AD Workbench, its secure, cloud-based data sharing and analysis platform and AD Connect, its online community.

DPUK is delivering ADDI’s Democratising Dementia Data (D3) project which will support them by enabling easier access to dementia-relevant data worldwide. Democratising data is the process of facilitating all researchers to easily work with data. This quickens the pace, and deepens the capability of their work.

On behalf of the dementia research community, ADDI supports rapid access to large multimodal datasets (comprising genomic, imaging and device data) to scientists wherever they work in the world.   

As part of the partnership, the team at Swansea University has been awarded £1 million to provide the infrastructure and develop an interface for federated data analysis between DPUK and other infrastructures to enable global access to dementia specific data using the AD Workbench.

Professor John Gallacher, Director of DPUK, said:

“Access to high-quality data is the biggest accelerator of scientific research.  This applies especially to complex conditions like dementia. We are delighted to work with ADDI to make research-ready data globally available for dementia research.” 

Professor Ronan Lyons, Associate Director at DPUK and DPUK Data Portal Lead, said: “Dementia is one of the biggest public health challenges facing us globally.   We are delighted to be working with our ADDI partners on this project which will allow researchers, via the AD Workbench, to get fast access to rich data to help transform our understanding of dementia.”

Dr. Tetsuyuki Maruyama, Executive Director at ADDI, said: “This partnership has the potential to accelerate research for Alzheimer’s disease and related dementias. By working together on the D3 project, ADDI and DPUK will enable greater data interoperability and make it easier for researchers to collaborate and bring an end to dementia.”  

Similar stories

DPUK blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Infections linked to higher risk of brain and mental health conditions for up to two years

A large study of more than 1 million matched patient pairs finds that serious infections across the body are followed by increased risks of psychiatric and neurological diagnoses, especially in adults

Potential use for blood biomarkers in dementia diagnosis where medical resources are limited

Blood biomarkers are highly accessible for use in diagnosis, and there is very strong potential for them to be valuable in low- and middle-income countries (LMICs) where they can be scalable and extend accurate diagnosis.

Innovative brain health clinic has now assessed 500 patients and improved accuracy of dementia diagnosis

One of the UK’s first Brain Health Clinics is marking two major milestones as it celebrates five years since it launched and more than 500 patients using its services.

Any level of alcohol consumption increases risk of dementia - new study

Led by the University of Oxford, Yale University, and the University of Cambridge, the research challenges previous suggestions that light-to-moderate drinking may have a protective effect against dementia.

Certain chronic health conditions associated with increased risk of dementia – new study

Developing cardiovascular, mental health and neurological-related illnesses before the age of 70 is associated with a greater risk of dementia later in life, with the more of these conditions accumulated the greater the risk, according to a new study by the University of Oxford.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.